Project Grant SB1AI191998
Award Date 7/22/26
Completion Date 6/30/29
Dollars Obligated $956K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Research Triangle Park, Durham, NC, USA
Similar Awards
- The Centers for Disease Control and Prevention awarded Redbud Labs, Inc. $45,162 on September 30, 2026, under the Protecting and Improving Health Globally program (CFDA 93.318) to develop an automated, compact sample-to-sequencer-ready system for extensively and multi-drug-resistant tuberculosis detection. Redbud Labs, a microfluidic chip manufacturer specializing in assay automation platforms, will perform the work in the United States through September 29, 2027. The company designs and...
- The National Institute of Allergy and Infectious Diseases awarded Triangle Biotechnology, Inc. one million dollars on July 20, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to commercialize nanodroplet technology for improved microbial lysis and DNA extraction from difficult-to-lyse samples. Triangle Biotechnology is developing SnapLyse, a proprietary cavitation-enhancing nanodroplet reagent paired with low-power sonication for efficient, high-throughput, and...
- The National Institute of Allergy and Infectious Diseases awarded Vivid Bioinnovations, PBC $299,991 on September 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop a spatially resolved single-cell DNA sequencing platform for spatial genomics with application to HIV reservoir mapping. The recipient will develop the first commercially viable spatial genomics platform integrating hydrogel-based spatial barcoding, droplet microfluidics, and Bayesian...
- The National Institute of Allergy and Infectious Diseases awarded Helixbind, Inc. $1,029,859 on July 16, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to advance development of an automated molecular diagnostic system for rapid characterization of bloodstream infections directly from whole blood. Helixbind is developing a sample-to-answer assay that identifies pathogens causing sepsis and antimicrobial-resistant organisms within approximately four hours,...
- The National Institute of Allergy and Infectious Diseases awarded Health Research, Inc. (Wadsworth Center Division) $403,756 on April 14, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to map the determinants of bedaquiline resistance in Mycobacterium tuberculosis. The recipient will use saturating mutagenesis to create a comprehensive database of loss-of-function mutations in the MMPR gene (RV0678) that confer bedaquiline resistance. The database will enable...
- The National Institute of Allergy and Infectious Diseases awarded The Rockefeller University $798,670 on June 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop bioinformatics-guided methods for discovering novel antibiotics from previously inaccessible microbial sources. The project couples direct nanopore metagenomic sequencing with synthetic bioinformatic natural products discovery methods to identify complete biosynthetic gene clusters from...
- The National Institute of Allergy and Infectious Diseases awarded Epicypher, Inc. $999,268 on August 21, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop DAF-SEQ, an amplification-compatible long-read sequencing chromatin accessibility profiling assay for primary immune cells. DAF-SEQ combines haplotype-phased sequence analysis with single-molecule and single-cell chromatin accessibility profiling, enabling researchers to resolve chromatin structure in...
- The National Institute of Allergy and Infectious Diseases awarded Northeastern University $650,221 on June 12, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop an efficient platform for antibiotic discovery by culturing and mining uncultured bacteria. The project, titled "An Efficient Platform for Antibiotic Discovery," addresses the challenge that the vast majority of bacteria on the planet do not grow in laboratory conditions. The recipient...
- The National Institute of Allergy and Infectious Diseases awarded $118,332 to the University of North Carolina at Charlotte on October 9, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop multifunctional RNA/DNA hybrid nanoassemblies capable of simultaneously activating the cGAS-STING and RIG-I immune pathways while incorporating real-time fluorescent monitoring. The approach involves engineering non-functional RNA/DNA hybrids carrying partial agonists...
- The National Institute of Allergy and Infectious Diseases awarded the Institute For Systems Biology $940,934 on June 12, 2026, for research on canonical and non-canonical phosphorylation events in bacterial pathogens under CFDA 93.855 (Allergy and Infectious Diseases Research). The project develops and applies engineered affinity reagents called phosphopeptide "superbinders" to interrogate phosphorylation in bacterial pathogens. Traditional immobilized metal affinity chromatography...